On Tuesday, Shares of Yamana Gold Inc. (USA)(NYSE:AUY), subtract -13.05% and closed at $3.73 in the last trading session. The last trading range of the stock ranges between $3.72 and $4.11. Yamana Gold Inc. engages in the exploration and development of precious metal properties in Brazil, Argentina, Chile, Mexico, and Canada. It explores for gold, silver, and copper. It mainly holds interests in the Chapada, El Peñón, Gualcamayo, Mercedes, Canadian Malartic, Minera Florida, and Jacobina properties.
Huntington Bancshares Incorporated (NASDAQ:HBAN), jumped 0.82% and closed at $9.88 in the last trading session. The last trading range of the stock ranges between $9.78 and $9.97. The company’s Market capitalization is $7.85 Billion with the total Outstanding Shares of 799.15 million. Huntington Bancshares Incorporated (HBAN) anticipates to report its third quarter earnings on Wednesday, October 26, 2016, before the market opening. A news release and supporting financial data will be available at that time on the company’s shareholder relations website.
Merck & Co., Inc. (NYSE:MRK), lost -0.10% and closed at $62.46 in the last trading session. The last trading range of the stock ranges between $61.94 and $62.95. During the 52-week trading session the minimum price at which share price traded, registered at $47.97 and reached to max level of $64.00. NewLink Genetics Corporation (NLNK), declared recently that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has issued a $24.8 million contract to a partner of NewLink Genetics to support the advanced development of the investigational rVSV∆G-ZEBOV GP (Ebola Zaire) vaccine candidate, designated V920.
The new award includes an additional $51 million of contract options which may be exercised by BARDA. BARDA has formerly awarded $76.8 million in contracts for development of V920. The new funding is in support of manufacturing facility readiness, manufacturing process qualification activities, and additional clinical trials to support regulatory approval of the V920 vaccine.